Telomir Pharmaceuticals (TELO) said Thursday that a preclinical study showed "significant" age reversal effects in subjects treated with Telomir-1, a compound designed to reverse aging and support longevity.
Among the effects were increased lifespan, improved mobility, and a measurable reversal of biological age markers, according to Telomir.
The company said it is collaborating with the Progeria Foundation to evaluate the effects of Telomir-1 on human progeria cell lines to advance the development of the compound as a potential treatment for children with progeria, a genetic disorder that causes accelerated aging.
Shares of Telomir Pharmaceuticals rose more than 12% in early trading Thursday.
Price: 4.74, Change: +0.54, Percent Change: +12.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。